Clinical Trials on Advanced Melanoma in United Kingdom

Total 4622 results

Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

Melanoma (Skin)

United States
Louisiana State University Health Sciences Center...

Terminated

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

Melanoma (Skin)

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); American Society of Clinical Oncology; Society...

Completed

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

Melanoma (Skin)

United States
University of Miami

Completed

Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery

Melanoma (Skin)

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Melanoma (Skin)

United States
St. Luke's Medical Center

Unknown

Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Baylor Health Care System
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Melanoma

Melanoma (Skin)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

Melanoma (Skin)

United States
Hoffmann-La Roche

Completed

A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States, Australia
Celgene
University of Arizona

Completed

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Malignant Melanoma

Canada, United States, Australia, United Kingdom, France, Italy, Spain, Germany, Netherlands
Novartis Pharmaceuticals

Completed

Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients

BRAF v600 Mutated Metastatic Melanoma

United States
University of Utah

Terminated

Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

Stage III or IV Melanoma

United States
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma

United States
AB Science

Terminated

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Metastatic Melanoma

France, Spain, Italy, United States, Czechia, Germany, Russian Federation
Sidney Kimmel Cancer Center at Thomas Jefferson...
Pfizer

Active, not recruiting

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage IIIC Intraocular Melanoma | Stage I Intraocular Melanoma | Stage IIA Intraocular Melanoma | Stage IIB Intraocular... and other conditions

United States
Hoffmann-La Roche

Completed

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

Malignant Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Incyte Corporation; University of Virginia

Completed

Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IV Uveal Melanoma | Stage IIIA Skin Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma | Recurrent Uveal Melanoma

United States
Jonsson Comprehensive Cancer Center
GlaxoSmithKline; Tesaro, Inc.

Completed

PET Imaging of the Immune System Using Analog Probes

Malignant Melanoma

United States
Jonsson Comprehensive Cancer Center
Pfizer

Completed

Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center
Pfizer

Completed

CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center
Pfizer; Schering-Plough

Completed

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

Metastatic Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Hoag Memorial Hospital Presbyterian

Completed

Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma

Melanoma (Skin)

United States
Blumenthal Cancer Center at Carolinas Medical Center

Unknown

Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

Melanoma (Skin)

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma

Melanoma (Skin)

United States
Mannkind Corporation

Completed

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

United States
Kari Kendra
Karyopharm Therapeutics Inc

Completed

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery (KPT-330)

Recurrent Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; National Cancer Institute (NCI); Medarex

Completed

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

Melanoma (Skin)

United States
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma

Melanoma (Skin)

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
Ohio State University Comprehensive Cancer Center
Celgene Corporation; National Comprehensive Cancer Network

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

Intraocular Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma

Melanoma (Skin)

United States
San Diego Pacific Oncology & Hematology Associates

Unknown

Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Suspended

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

United States

Clinical Trials on Advanced Melanoma in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations